Join the Libtayo group to help and get support from people like you.
Libtayo News
Immune Checkpoint Inhibitors Can Be Active in Penile Cancer
WEDNESDAY, Aug. 23, 2023 – Immune checkpoint inhibitors (ICIs) are active in some patients with penile cancer (PeCa), according to a study published online Aug. 11 in the Journal of the National...
T-Cell Tolerant Fraction Can Predict Immunotherapy Toxicity
MONDAY, Aug. 21, 2023 – The T-cell tolerant fraction predicts clinically significant immune-related adverse events (irAEs) among patients with cancer treated with immune checkpoint inhibitors...
Immune-Based Cancer Drugs Offer Hope Against Penile Cancers
TUESDAY, Aug. 15, 2023 – Men who have a rare cancer of the penis may have a new treatment option, according to researchers who found promise in immunotherapy. This new study focused on cancer that...
Could Loss of the Y Chromosome Help Speed Cancers in Men?
WEDNESDAY, June 21, 2023 – It’s common knowledge that loss is a part of male aging — loss of hair, loss of muscle tone, loss of vision or hearing. But men growing older also start losing the very thi...
Libtayo (cemiplimab-rwlc) in Combination with Chemotherapy Approved by the FDA as First-line Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC)
Approval based on superior survival outcomes of Libtayo plus chemotherapy, compared to chemotherapy alone, in a patient population with a wide range of disease characteristics Second advanced NSCLC...
FDA Approves Libtayo (cemiplimab-rwlc) Monotherapy for Patients with First-line Advanced Non-Small Cell Lung Cancer with PD-L1 Expression of ≥50%
TARRYTOWN, N.Y. and PARIS, Feb. 22, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved the PD-...
FDA Approves Libtayo (cemiplimab-rwlc) as First Immunotherapy Indicated for Patients with Advanced Basal Cell Carcinoma
TARRYTOWN, N.Y. and PARIS, Feb. 9, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) approved the PD-1 ...
FDA Approves Libtayo (cemiplimab-rwlc) for Advanced Cutaneous Squamous Cell Carcinoma
September 28, 2018 – The U.S. Food and Drug Administration today approved Libtayo (cemiplimab-rwlc) injection for intravenous use for the treatment of patients with metastatic cutaneous squamous...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Basal Cell Carcinoma, Non-Small Cell Lung Cancer